» Articles » PMID: 14670925

Involvement of Notch-1 Signaling in Bone Marrow Stroma-mediated De Novo Drug Resistance of Myeloma and Other Malignant Lymphoid Cell Lines

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 2003 Dec 13
PMID 14670925
Citations 117
Authors
Affiliations
Soon will be listed here.
Abstract

The bone marrow (BM) microenvironment plays a critical role in malignant cell growth, patient survival, and response to chemotherapy in hematologic malignancies. However, mechanisms associated with this environmental influence remain unclear. In this study, we investigated the role of Notch family proteins in myeloma and other malignant lymphoid cell line growth and response to chemotherapeutic drugs. All 8 tested cell lines expressed Notch-3 and Notch-4; 7 cell lines expressed Notch-1; and 6 expressed Notch-2 proteins. Interaction with BM stroma (BMS) activated Notch signaling in tumor cells. However, activation of only Notch-1, but not Notch-2, resulted in protection of tumor cells from melphalan- and mitoxantrone-induced apoptosis. This protection was associated with up-regulation of p21(WAF/Cip) and growth inhibition of cells. Overexpression of Notch-1 in Notch-1(-) U266 myeloma cells up-regulated p21 and resulted in protection from drug-induced apoptosis. Thus, this is a first report demonstrating that Notch-1 signaling may be a primary mechanism mediating the BMS influence on hematologic malignant cell growth and survival.

Citing Articles

A comprehensive review of oncogenic Notch signaling in multiple myeloma.

Roosma J PeerJ. 2024; 12:e18485.

PMID: 39619207 PMC: 11608568. DOI: 10.7717/peerj.18485.


Pathways to therapy resistance: The sheltering effect of the bone marrow microenvironment to multiple myeloma cells.

Bhowmick K, von Suskil M, Al-Odat O, Elbezanti W, Jonnalagadda S, Budak-Alpdogan T Heliyon. 2024; 10(12):e33091.

PMID: 39021902 PMC: 11252793. DOI: 10.1016/j.heliyon.2024.e33091.


A NOTCH3-CXCL12-driven myeloma-tumor niche signaling axis promotes chemoresistance in multiple myeloma.

Sabol H, Ashby C, Adhikari M, Anloague A, Kaur J, Khan S Haematologica. 2024; 109(8):2606-2618.

PMID: 38385272 PMC: 11290536. DOI: 10.3324/haematol.2023.284443.


The Potential of JAG Ligands as Therapeutic Targets and Predictive Biomarkers in Multiple Myeloma.

Platonova N, Lazzari E, Colombo M, Falleni M, Tosi D, Giannandrea D Int J Mol Sci. 2023; 24(19).

PMID: 37834003 PMC: 10572399. DOI: 10.3390/ijms241914558.


CK1δ and CK1ε Signaling Sustains Mitochondrial Metabolism and Cell Survival in Multiple Myeloma.

Burger K, Fernandez M, Meads M, Sudalagunta P, Oliveira P, Canevarolo R Cancer Res. 2023; 83(23):3901-3919.

PMID: 37702657 PMC: 10690099. DOI: 10.1158/0008-5472.CAN-22-2350.